Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 3
Submit an article Journal homepage
54
Views
1
CrossRef citations to date
0
Altmetric
Reviews

Phosphodiesterase type 5 inhibitors: a viable treatment option for lower urinary tract symptoms?

Konstantinos Hatzimouratidis Aristotle University of Thessaloniki, 2nd Department of Urology, 54006 Thessaloniki, Greece +30 23 10991543; +30 23 10676092; [email protected]
Pages 245-254 | Published online: 09 May 2009

Bibliography

  • Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003;44(6):637-49
  • Robertson C, Link CL, Onel E, et al. The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU Int 2007;99(2):347-54
  • McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005;47(6):838-45
  • Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005;47(6):824-37
  • Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005;96(2):313-21
  • AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003;170(2 Pt 1):530-47
  • Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs 2005;65(12):1621-50
  • Sairam K, Kulinskaya E, McNicholas TA, et al. Sildenafil influences lower urinary tract symptoms. BJU Int 2002;90(9):836-9
  • Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006;3(4):662-7
  • Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281(6):537-44
  • Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 2000;12(6):305-11
  • Braun MH, Sommer F, Haupt G, et al. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical ‘aging male’ symptoms? Results of the ‘Cologne Male Survey’. Eur Urol 2003;44(5):588-94
  • Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, et al. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001;166(2):569-74; discussion 74-5
  • Blanker MH, Bohnen AM, Groeneveld FP, et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 2001;49(4):436-42
  • Blanker MH, Bosch JL, Groeneveld FP, et al. Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity. Urology 2001;57(4):763-8
  • Boyle P, Robertson C, Mazzetta C, et al. The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study. BJU Int 2003;92(7):719-25
  • Nicolosi A, Glasser DB, Moreira ED, Villa M. Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study. Int J Impot Res 2003;15(4):253-7
  • Nicolosi A, Moreira ED Jr, Shirai M, et al. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology 2003;61(1):201-6
  • Hansen BL. Lower urinary tract symptoms (LUTS) and sexual function in both sexes. Eur Urol 2004;46(2):229-34
  • Brookes ST, Link CL, Donovan JL, McKinlay JB. Relationship between lower urinary tract symptoms and erectile dysfunction: results from the Boston Area Community Health Survey. J Urol 2008;179(1):250-5; discussion 5
  • Shiri R, Hakkinen JT, Hakama M, et al. Effect of lower urinary tract symptoms on the incidence of erectile dysfunction. J Urol 2005;174(1):205-9; discussion 9
  • Shiri R, Hakkinen J, Koskimaki J, et al. Association between the bothersomeness of lower urinary tract symptoms and the prevalence of erectile dysfunction. J Sex Med 2005;2(3):438-44
  • Shiri R, Hakkinen J, Koskimaki J, et al. Erectile dysfunction influences the subsequent incidence of lower urinary tract symptoms and bother. Int J Impot Res 2007;19(3):317-20
  • Mondul AM, Rimm EB, Giovannucci E, et al. A prospective study of lower urinary tract symptoms and erectile dysfunction. J Urol 2008;179(6):2321-6
  • Ponholzer A, Madersbacher S. Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment. Int J Impot Res 2007;19(6):544-50
  • McVary KT, McKenna KE. The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidence. Curr Urol Rep 2004;5(4):251-7
  • Bloch W, Klotz T, Loch C, et al. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 1997;33(1):1-8
  • Takeda M, Tang R, Shapiro E, et al. Effects of nitric oxide on human and canine prostates. Urology 1995;45(3):440-6
  • Guh JH, Hwang TL, Ko FN, et al. Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol 1998;53(3):467-74
  • Uckert S, Kuthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001;166(6):2484-90
  • Fawcett L, Baxendale R, Stacey P, et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 2000;97(7):3702-7
  • McVary KT, Razzaq A, Lee C, et al. Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod 1994;51(1):99-107
  • Golomb E, Rosenzweig N, Eilam R, Abramovici A. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J Androl 2000;21(1):58-64
  • Hale TM, Okabe H, Bushfield TL, et al. Recovery of erectile function after brief aggressive antihypertensive therapy. J Urol 2002;168(1):348-54
  • Medina JJ, Parra RO, Moore RG. Benign prostatic hyperplasia (the aging prostate). Med Clin North Am 1999;83(5):1213-29
  • Heidler S, Temml C, Broessner C, et al. Is the metabolic syndrome an independent risk factor for erectile dysfunction? J Urol 2007;177(2):651-4
  • McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005;174(4 Pt 1):1327-433
  • Bing W, Chang S, Hypolite JA, et al. Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am J Physiol Renal Physiol 2003;285(5):F990-7
  • Chang S, Hypolite JA, Zderic SA, et al. Enhanced force generation by corpus cavernosum smooth muscle in rabbits with partial bladder outlet obstruction. J Urol 2002;167(6):2636-44
  • Tarcan T, Azadzoi KM, Siroky MB, et al. Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Br J Urol 1998;82(Suppl 1):26-33
  • Ponholzer A, Temml C, Wehrberger C, et al. The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur Urol 2006;50(3):581-6
  • Kohler TS, McVary KT. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol 2009;55(1):38-48
  • Lue TF, Giuliano F, Montorsi F, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004;1(1):6-23
  • Wespes E, Amar E, Hatzichristou D, et al. EAU guidelines on erectile dysfunction: an update. Eur Urol 2006;49(5):806-15
  • Uckert S, Oelke M, Stief CG, et al. Immunohistochemical distribution of cAMP-and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006;49(4):740-5
  • McVary KT, Monnig W, Camps JL Jr, et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007;177(3):1071-7
  • McVary KT, Kaufman J, Young JM, Tseng LJ. Sildenafil citrate improves erectile function: a randomised double-blind trial with open-label extension. Int J Clin Pract 2007;61(11):1843-9
  • McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177(4):1401-7
  • Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose-finding study. J Urol 2008;180(4):1228-34
  • Stief CG, Porst H, Neuser D, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53(6):1236-44
  • McVary KT. Unexpected insights into pelvic function following phosphodiesterase manipulation: what's next for urology? Eur Urol 2006;50(6):1153-6
  • Chai TC, Belville WD, McGuire EJ, Nyquist L. Specificity of the American Urological Association voiding symptom index: comparison of unselected and selected samples of both sexes. J Urol 1993;150(5 Pt 2):1710-3
  • Chapple CR, Wein AJ, Abrams P, et al. Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol 2008;54(3):563-9
  • Giuliano F. Lower urinary tract symptoms and sexual dysfunction: a common approach. BJU Int 2008;101(Suppl 3):22-6
  • Oger S, Behr-Roussel D, Gorny D, et al. Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum. J Sex Med 2008;5(4):935-45
  • Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007;51(6):1717-23
  • Giuliano F, Kaplan SA, Cabanis MJ, Astruc B. Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 2006;67(6):1199-204
  • Bechara A, Romano S, Casabe A, et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008;5(9):2170-8
  • Ng CF, Wong A, Cheng CW, et al. Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia. J Urol 2008;180(3):1042-6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.